Floatz logo

Cladribine

Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome

Explore 75 assets in Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
Floatz Rating
BB64/100
Confidence
Indicative
v0.2
Sponsor
University of Michigan Rogel Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
Terminated
Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes
Active Not Recruiting
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
Completed
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Recruiting
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Completed

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome

AssetSponsorPhaseRating
Cladribine (this asset)University of Michigan Rogel Cancer CenterP2BB · 64
NivestimCity of Hope Medical CenterP2/3BBB
DaunomycinNational Cancer Institute (NCI)P3BBB
CytarabineNational Cancer Institute (NCI)P3BBB
IdarubicinFred Hutchinson Cancer CenterP2/3BB
EtoposideM.D. Anderson Cancer CenterP3BB
CyclophosphamideFred Hutchinson Cancer CenterP3BB
MelphalanCity of Hope Medical CenterP2BB
MitoxantroneInstitut de Recherches Internationales ServierP2BB

+42 more in the Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome cohort

Other indications for Cladribine

IndicationSponsorPhaseRating
Relapsing-Remitting Multiple SclerosisP4BBB · 76
Lymphoblastic LymphomaP4BBB · 75
Multiple SclerosisP4BBB · 72

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Cladribine in Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/cladribine-therapy-related-acute-myeloid-leukemia-and-myelodysplastic-syndrome

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →